Company
Evgen Pharma plc
Headquarters: Wilmslow, United Kingdom
Employees: 8
CEO: Dr. Huw Jones BSc, Ph.D.
Market Cap
£3.4 Million
GBP as of July 1, 2024
US$4.3 Million
Evgen Pharma plc Categories
United Kingdom Healthcare BiotechnologyUnited Kingdom Healthcare United Kingdom Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases. Its core technology is Sulforadex, a means of synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic and stabilized form of sulforaphane that is in Phase II clinical trials for the treatment of metastatic breast cancer; in preclinical stage for glioma and glioblastoma; and in Phase IIb for treating acute respiratory infections. Evgen Pharma plc was founded in 2007 and is headquartered in Nether Alderley, the United Kingdom.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Evgen Pharma plc has the following listings and related stock indices.
Stock: LSE: EVG wb_incandescent